Basic Neurosciences · Paper A
Catecholamine synthesis
Dopamine, noradrenaline and adrenaline are made in a single chain, each one built from the last. Blocking the very first enzyme in this chain would collapse every downstream product together, e.g. one drug target could cut all three transmitters at once. This shared pathway is why one enzyme controls the output of three different neurotransmittersA chemical messenger that nerve cells release to signal to the next cell.Read more →.
Tyrosine is converted to L-DOPA by tyrosine hydroxylase, the rate-limiting step for the whole pathway. L-DOPA is converted to dopamine by DOPA decarboxylase. Dopamine is converted to noradrenaline by dopamine beta-hydroxylase, and noradrenaline is converted to adrenaline by PNMT. Dopamine itself is broken down by MAOMonoamine oxidase, an enzyme that breaks down mood-related brain chemicals.Read more → (monoamine oxidase) and COMT into homovanillic acid (HVA); e.g. measuring homovanillic acid in a patient's urine, a raised level reflects increased dopamine turnover through this exact chain. Clinically, tyrosine hydroxylase, as the rate-limiting enzyme, is the single most exam-relevant step to remember.
Suppose an exam question asks which single enzyme, if genetically deficient, would lower dopamine, noradrenaline, and adrenaline levels all at once, while leaving serotonin completely unaffected. You cannot answer that from memory of drug names alone: you need the actual assembly-line order of the pathway. Catecholamines are a family of three and hormones, dopamine, noradrenaline (also called norepinephrine), and adrenaline (also called epinephrine), that are all built from the same amino acid, tyrosine, along one shared production line. Understanding this single chain is one of the highest-yield pieces of basic neuroscience for the exam because it explains, in one diagram, why drugs, enzyme deficiencies, and certain tumours can affect one, two, or all three of these transmitters depending on exactly where in the chain they act.
A useful way to picture the pathway is as a factory assembly line: tyrosine enters at one end, and at each station a specific enzyme (a protein catalyst that speeds up one specific chemical reaction) converts the molecule into the next product, until adrenaline comes off the far end. If you understand the order of the stations and which enzyme works at each one, most exam questions about this topic become straightforward.
The single most exam-relevant fact in this whole topic is that tyrosine hydroxylase, the very first enzyme in the chain, is also the rate-limiting step (the slowest, bottleneck step that controls the speed of the whole pathway). Because every catecholamine downstream depends on this first conversion, anything that inhibits tyrosine hydroxylase reduces dopamine, noradrenaline, and adrenaline all together, not just one of them: miss this and you will misattribute a whole-pathway effect to a later, more specific step.
Tyrosine is converted into L-DOPA (levodopa) by tyrosine hydroxylase: the rate-limiting step described above. L-DOPA is then converted into dopamine by DOPA decarboxylase (also called aromatic L-amino acid decarboxylase), a step that happens quickly once L-DOPA is available; this is exactly why administering L-DOPA, as in Parkinson's disease treatment, reliably boosts dopamine levels in the brain, since the conversion enzyme is abundant and fast. Dopamine is converted into noradrenaline by dopamine beta-hydroxylase, a step that occurs inside the storage vesicles of neurons and in the adrenal medulla (the inner part of the adrenal gland). Finally, noradrenaline is converted into adrenaline by PNMT (phenylethanolamine N-methyltransferase), a step that happens almost exclusively in the adrenal medulla, which is why adrenaline is mainly a circulating hormone released from the adrenal gland, whereas noradrenaline and dopamine act more widely as within the brain and peripheral nervous system.
Dopamine, noradrenaline, and adrenaline are broken down by two main enzymes, (monoamine oxidase) and COMT (catechol-O-methyltransferase), which together degrade catecholamines into inactive metabolites. One important breakdown product is homovanillic acid (HVA), the main metabolite of dopamine; measuring HVA in urine or cerebrospinal fluid gives a rough index of how much dopamine turnover has occurred. Now work through the opening question: DOPA decarboxylase deficiency would only block the second step, so dopamine, noradrenaline, and adrenaline would all still be reduced, since everything downstream of dopamine depends on it too. PNMT deficiency, by contrast, would only reduce adrenaline, since dopamine and noradrenaline are made before that final step and would be unaffected. Only a deficiency in tyrosine hydroxylase, the very first and rate-limiting enzyme, would reduce all three catecholamines together, while leaving serotonin completely untouched.
A very common exam trap is confusing catecholamine synthesis with serotonin synthesis. Serotonin is made from a different amino acid, tryptophan, converted by a different rate-limiting enzyme, tryptophan hydroxylase, which is structurally similar in name to tyrosine hydroxylase but works on a completely separate pathway with no shared intermediate. If a question describes a step or an inhibitor acting on serotonin, tryptophan hydroxylase is the rate-limiting enzyme in question, not tyrosine hydroxylase, and nothing that happens in that pathway touches dopamine, noradrenaline, or adrenaline levels. A second look-alike worth separating is the symptom picture of catecholamine excess versus other causes of similar sympathetic symptoms: palpitations, sweating, and anxiety from a phaeochromocytoma can closely mimic a panic attack or hyperthyroidism, which is precisely why biochemical confirmation, not symptoms alone, is what actually distinguishes them.
Phaeochromocytoma, a rare catecholamine-secreting tumour usually of the adrenal medulla, causes excess production all along this chain and is diagnosed partly through elevated urinary or plasma catecholamines and their metabolites (metanephrines), alongside imaging such as CT or MIBG scanning, following guidance from bodies such as NICE and the Endocrine Society. On the other side of the pathway, Parkinson's disease is diagnosed clinically, from the characteristic motor features of dopamine deficiency, rather than by directly measuring dopamine itself, since dopamine cannot be reliably sampled from the brain in routine practice: the biochemistry here is inferred from the clinical picture, not measured directly, which is a useful contrast to phaeochromocytoma's directly measurable excess.
Management is typically surgical resection of a phaeochromocytoma after careful alpha-blockade to prevent a hypertensive crisis during induction of anaesthesia, since suddenly removing a catecholamine-secreting tumour without first blocking its peripheral effects can cause dangerous swings in blood pressure. In Parkinson's disease, loss of neurons reduces dopamine, and treatment with L-DOPA works precisely because it bypasses the rate-limiting tyrosine hydroxylase step and is converted directly to dopamine by DOPA decarboxylase, following management principles set out in NICE guidance on Parkinson's disease. In psychiatry more broadly, drugs affecting this pathway (stimulants that increase catecholamine release, or antipsychotics that block downstream dopamine receptors) are best understood against this same four-step backbone, since knowing where a drug acts on the chain predicts which transmitters it will affect.
When a question asks which enzyme deficiency affects all three catecholamines but spares serotonin, the answer is always the first, rate-limiting step of the catecholamine chain, tyrosine hydroxylase, never a later, more specific enzyme like PNMT that only touches the final product.
Tyrosine leads to L-DOPA leads to dopamine leads to noradrenaline leads to adrenaline via tyrosine hydroxylase (rate-limiting), DOPA decarboxylase, dopamine beta-hydroxylase, and PNMT, in that fixed order, entirely separate from the tryptophan-based serotonin pathway.